NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

And they get the treatment in the doctor’s office, not hospitalized and with virtually no side-effects. I doubt regulators will look at it as you do.

Quality of life is improved, the potential for patients to live longer is established and has a compensatory value as well, some substantial patients will live many months longer than the few you indicated and that also has compensatory value, and then one looks at the alternatives, which is not “nothing” else.

I doubt very much that regulators are going to find reasons to say no on DCVax-L as part of the new standard of care and the new SOC for recurrent patients.

But you can argue in the abstract all that you’d like.